Arvinas, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for ARVN, updated each market day.
ARVN AI Sentiment
AI sees no strong directional signal for Arvinas, Inc stock over the next 10 market days.
Prediction date: July 24, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Sector
Exchange
Market Cap
$523,912,127
Cap Tier
Employees
246
Headquarters
NEW HAVEN, CT
Listed Since
Sept. 27, 2018
Website
ARVN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ARVN Volatility
Arvinas, Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
